These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 24150795)
21. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Rittmaster RS Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794 [TBL] [Abstract][Full Text] [Related]
22. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515 [TBL] [Abstract][Full Text] [Related]
23. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396 [TBL] [Abstract][Full Text] [Related]
24. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. Bruchovsky N; Sadar MD; Akakura K; Goldenberg SL; Matsuoka K; Rennie PS J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):397-404. PubMed ID: 9010345 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry. Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165 [TBL] [Abstract][Full Text] [Related]
26. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Schmidt LJ; Ballman KV; Tindall DJ Prostate; 2007 Jul; 67(10):1111-20. PubMed ID: 17477363 [TBL] [Abstract][Full Text] [Related]
28. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]. Bartsch G; Rittmaster RS; Klocker H Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858 [TBL] [Abstract][Full Text] [Related]
29. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Biancolella M; Valentini A; Minella D; Vecchione L; D'Amico F; Chillemi G; Gravina P; Bueno S; Prosperini G; Desideri A; Federici G; Bernardini S; Novelli G Invest New Drugs; 2007 Oct; 25(5):491-7. PubMed ID: 17636412 [TBL] [Abstract][Full Text] [Related]
30. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate. Kumar VL; Wahane VD Indian J Med Sci; 2008 Apr; 62(4):167-75. PubMed ID: 18445985 [TBL] [Abstract][Full Text] [Related]
31. Actions of 5alpha-reductase inhibitors on the epididymis. Robaire B; Henderson NA Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520 [TBL] [Abstract][Full Text] [Related]
32. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Schmidt LJ; Regan KM; Anderson SK; Sun Z; Ballman KV; Tindall DJ Prostate; 2009 Dec; 69(16):1730-43. PubMed ID: 19676081 [TBL] [Abstract][Full Text] [Related]
33. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461 [TBL] [Abstract][Full Text] [Related]
34. An overview on 5alpha-reductase inhibitors. Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888 [TBL] [Abstract][Full Text] [Related]
35. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854 [TBL] [Abstract][Full Text] [Related]
36. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Mohler JL; Titus MA; Wilson EM Clin Cancer Res; 2011 Sep; 17(18):5844-9. PubMed ID: 21705451 [TBL] [Abstract][Full Text] [Related]
37. Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Elo JP; Akinola LA; Poutanen M; Vihko P; Kyllönen AP; Lukkarinen O; Vihko R Int J Cancer; 1996 Mar; 66(1):37-41. PubMed ID: 8608963 [TBL] [Abstract][Full Text] [Related]
38. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. Shao TC; Li H; Ittmann M; Cunningham GR J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058 [TBL] [Abstract][Full Text] [Related]
39. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443 [No Abstract] [Full Text] [Related]
40. 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. Délos S; Carsol JL; Fina F; Raynaud JP; Martin PM Int J Cancer; 1998 Mar; 75(6):840-6. PubMed ID: 9506528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]